Colorectal cancer (CRC) is often diagnosed at an advanced stage when tumor cell
dissemination has taken place. Chemo-and targeted therapies provide only a limited …

Metastatic colorectal cancer (mCRC) remains incurable in most cases, but survival has
improved with advances in cytotoxic chemotherapy and targeted agents. However, the …

This selection from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines)
for Colon Cancer focuses on systemic therapy options for the treatment of metastatic …

The most recent version of the European Society for Medical Oncology (ESMO) consensus
guidelines for the treatment of patients with metastatic colorectal cancer (mCRC) was …

Median overall survival (OS) of patients with metastatic colorectal cancer (mCRC) has
reached up to 30 months in recent clinical trials of first line therapies. Following disease …

The epidermal growth factor receptor (EGFR) is a transmembrane glycoprotein that is part of
the family of tyrosine kinase receptors. The binding of EGFR to its cognate ligands leads to …

Colorectal cancer is the third most common cancer worldwide, and incidence is rising in
younger individuals. Anti-EGFR antibodies, including cetuximab and panitumumab, have …

The treatment of metastatic colorectal cancer has evolved over the last two decades with the
FDA approval of several cytotoxic, biological, and targeted agents. In this paper, we review …

Colorectal cancer (CRC) is one of the most common malignancies, accounting for
approximately 10% of global cancer incidence and mortality. Approximately 20% of patients …

Background: Over the last few years only one large randomized phase III study has tried to
prospectively assess the safety of cetuximab and panitumumab in a head-to-head …